Is Mycobacterial InhA a Suitable Target for Rational Drug Design?
ChemMedChem · 2025-07 · 20 (13)
DOI: 10.1002/cmdc.202500079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 29.04.2025. Verfasst von Julien Rizet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), 205 route d…. Hauptthemen laut MEDLINE: Antitubercular Agents, Bacterial Proteins, Drug Design, Enzyme Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
InhA, an NAD‐dependent enoyl‐acyl carrier protein reductase, is involved in the biosynthesis of mycolic acids, specific lipids to mycobacteria. InhA is the target of isoniazid, a first‐line antituberculosis drug used since the 1950s. Isoniazid is a prodrug that needs to be activated by the catalase‐peroxidase KatG. Due to resistance problems, a substantial amount of work has been carried out to identify or design direct inhibitors of InhA, demonstrating that this enzyme is still considered a relevant target for the discovery of new antituberculosis drugs. Much of this work included the resolution of crystallographic structures. Indeed, over a hundred structures have been deposited in the Protein Data Bank for different forms of the enzyme (apo, holo, and complexes), demonstrating a real crystalline polymorphism. Taken together, these structures constitute a valuable dataset. However, the complete decoding of the enzyme's properties and its inhibition literally comes up against its molecular plasticity at the level of a motif essential to the definition of the active site: the substrate‐binding loop. In this article, a detailed analysis of this structural dataset is proposed, describing in particular the different families of inhibitors and attempting to establish structural links of causality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), 205 route de Narbonne, BP 64182, 31077, Toulouse Cedex 4, France.
- Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), 118 route de Narbonne, 31062, Toulouse Cedex 09, France.
ORCID-Profile: Laurent Maveyraud, David Rengel, Valérie Guillet, Frédéric Rodriguez, Christian Lherbet, Lionel Mourey
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Rizet, J., Maveyraud, L., Rengel, D., Guillet, V., Publicola, G., Rodriguez, F., Lherbet, C., & Mourey, L. (2025). Is Mycobacterial InhA a Suitable Target for Rational Drug Design?. ChemMedChem, 20(13). https://doi.org/10.1002/cmdc.202500079
Vancouver
Rizet J, Maveyraud L, Rengel D, Guillet V, Publicola G, Rodriguez F, et al. Is Mycobacterial InhA a Suitable Target for Rational Drug Design?. ChemMedChem. 2025;20(13). doi:10.1002/cmdc.202500079
BibTeX
@article{Rizet2025,
author = {Rizet, Julien and Maveyraud, Laurent and Rengel, David and Guillet, Valérie and Publicola, Gabriel and Rodriguez, Frédéric and Lherbet, Christian and Mourey, Lionel},
title = {Is Mycobacterial InhA a Suitable Target for Rational Drug Design?},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {13},
doi = {10.1002/cmdc.202500079}
}
EUVIMED